Jordan Porter
Family · Pittsfield, MENPI 1285286591
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,259 and has fallen 89.3% since, to $135 in 2025. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$420
- AstraZeneca$262
- Sanofi-aventis U.S. LLC$194
- Takeda Pharmaceuticals U.S.A., Inc.$176
- Novo Nordisk$162
- Gilead$152
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,38094%
- Education$1506%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $420 |
| AstraZeneca | 16 | $262 |
| Sanofi-aventis U.S. LLC | 11 | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $176 |
| Novo Nordisk | 9 | $162 |
| Gilead | 2 | $152 |
| Neurocrine Biosciences, Inc. | 1 | $152 |
| GSK | 11 | $139 |
| Bayer | 7 | $136 |
| Merck | 7 | $121 |
| Astellas Pharma US Inc | 2 | $120 |
| Pfizer | 4 | $69 |
| Boehringer Ingelheim | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $63 |
| Eisai Inc. | 3 | $61 |
| Johnson & Johnson | 2 | $55 |
| Amgen | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Indivior Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Novartis | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,530 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 24 | $36,444 |
| JardianceEmpagliflozin | 22 | $33,003 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $28,995 |
| EliquisApixaban | 21 | $25,010 |
| OzempicSemaglutide | 16 | $24,854 |
| FarxigaDapagliflozin Propanediol | 23 | $23,414 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $2,628 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,285 |
| Levothyroxine Sodium | 76 | $698 |
| Omeprazole | 42 | $641 |
| Pregabalin | 11 | $613 |
| Atorvastatin Calcium | 48 | $468 |
| Gabapentin | 36 | $457 |
| Oxycodone Hcl | 26 | $441 |
| Lisinopril | 64 | $384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $19 | $36,44424 claims |
| Boehringer IngelheimJardiance | $63 | $33,00322 claims |
| GSKTrelegy Ellipta | $139 | $28,99521 claims |
| PfizerEliquis | $69 | $25,01021 claims |
| Novo NordiskOzempic | $162 | $24,85416 claims |
| AstraZenecaFarxiga | $262 | $23,41423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Pittsfield
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
- Kristen Schroeder-CyrBrunswick$5K
- Liana KellyBrunswick$5K
- Natalie BubierLewiston$5K
- Holly JamesYork$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.